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Abstract
Background: Prostate cancer (PCa) incidences vary with genetic, geographical and ethnic dietary background of
patients while angiogenesis is modulated through exquisite interplay of tumor-stromal interactions of biological
macromolecules. We hypothesized that comprehensive analysis of four biomarkers modulating angiogenesis in
PCa progression in two diverse populations might explain the variance in the incidence rates.
Results: Immunohistochemical analysis of 42 PCa biopsies reveals that though Anx-II expression is lost in both
the Indian and American population with Gleason scores (GS) ranging between 6 and 10, up to 25 % of cells in
the entire high grade (GS > 8) PD PCa samples from US show intense focal membrane staining for Anx-II unlike
similarly graded specimens from India. Consistent with this observation, the prostate cancer cell lines PC-3, DU-
145 and MDA PCa 2A, but not LNCaP-R, LNCAP-UR or MDA PCa 2B cell lines, express Anx-II. Transcriptional
reactivation of Anx-II gene with Aza-dC could not entirely account for loss of Anx-II protein in primary PCa.
Cyclooxygenase-2 (COX-2) was moderately expressed in most of high grade PIN and some MD PCa and
surrounding stroma. COX-2 was not expressed in PD PCa (GS ~7–10), while adjacent smooth muscles cells
stained weakly positive. Decorin expression was observed only in high grade PIN but not in any of the prostate
cancers, atrophy or BPH while stromal areas of BPH stained intensively for DCN and decreased with advancing
stages of PCa. Versican expression was weak in most of the MD PCa, moderate in all of BPH, moderately focal
in PD PC, weak and focal in PIN, atrophy and adjacent stroma.
Conclusions: Expression of pro- and anti-angiogenic modulators changes with stage of PCa but correlates with
angiogenic status. Focal membrane staining of Anx-II reappears in high grade PCa specimens only from US
indicating differential expression of Anx-II. COX-2 stained stronger in American specimens compared to Indian
specimens. The sequential expression of DCN and VCN in progressive stages was similar in specimens from India
and USA indicating no population-based differences. The mechanistic and regulatory role of Anx-II in PCa
progression warrants further investigation.
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Background
Prostate cancer is the most common form of cancer in
males and the second leading cause of cancer related
death. The latest estimates of global incidences of PCa
show that it is more common in countries with higher
proportions of elderly men in their population and PCa
accounts for about 15% of all cancers in developed coun-
tries as compared to 4% in developing countries [1]. The
incidence of PCa increased in the American population in
the late 1980s and early 1990s, but increased incidence
rates have also occurred in low risk countries like India.
While the incidence rates may be low in India, one study
found that 84% of patients in India present with advanced
stages of PCa [2]. Another study encompassing 110
Indian PCa specimens, found that high grade PIN was
present in 85% of the samples [3]. In India, early detec-
tion of PCa is difficult because of the high-cost of PSA
screening resulting in limited PSA screening, and the fact
that there are rarely any symptoms in the early stages of
the disease. Thus, it is important to understand the molec-
ular changes associated with early stages of PCa as well as
progression of the disease. Numerous biomarkers have
been identified; however, our particular study focuses on
specific biomarkers that are related to interaction of
tumor cell and stromal microenvironment and its cooper-
ative effect in prostate cancer progression through promo-
tion of angiogenesis. We studied archival prostate tissues
from India and USA patient populations to investigate
ethnic differences in the expression pattern of biomarkers
that could point to genetic and lifestyle-related contribu-
tion to prostate cancer progression.
Angiogenesis is the formation of new blood vessels from
pre-existing ones. It is well known that any increase in
tumor mass must be preceded by an increase in vascular
supply that helps support growth and dissemination of
tumor cells [4]. The process of angiogenesis is a result of
changes in the equilibrium between positive and negative
angiogenic factors [5]. Some important mediators that
have been studied include acidic and basic fibroblast
growth factors (FGFs), vascular endothelial growth factors
(VEGFs), transforming growth factors (TGF-α and TGF-β),
platelet-derived growth factor (PDGF), angiogenins
(ANG), interleukin (IL)-8, and tumor necrosis factor-
alpha (TNFα) [6–8]. Interestingly, both the development
of a vascular supply and stromal support are essential for
tumor growth [9,10]. To test this hypothesis, we investi-
gated biomarkers that are known as direct or indirect
modulators of angiogenesis through interaction in the
extracellular matrix milieu with other biomolecules
involved in tumor progression. To our knowledge this is
the first study with a comprehensive approach to study
prostate cancer progression involving probable crosstalk
of angiogenic modulators.
Anx-II belongs to a family of Ca2+-dependent phospholi-
pid and membrane binding proteins called annexins.
Anx-II is implicated in the tissue plasminogen activator
(tPA)-plasmin pathway, and facilitates formation of a
complex that permits plasmin formation known to stim-
ulate matrix remodeling and activation of matrix metallo-
proteinases (MMPs) required for angiogenesis [11,12].
Anx-II has been frequently found to be lost in primary
prostate adenocarcinoma [13] but is known to be over-
expressed in other type of cancers [14–16].
Cyclooxygenase-2 (COX-2) is the inducible form of
cyclooxygenase that converts arachidonic acid to prostag-
landins. Its expression is undetectable in normal tissue,
but COX-2 is expressed in higher amounts in inflamed
and malignant tissues. Prostaglandins are known pro-ang-
iogenic factors and cells that overexpress COX-2 are able
to stimulate endothelial migration and tube formation
[17]. COX-2 is also said to contribute to tumor progres-
sion by increasing adhesion of cells to the extracellular
matrix (ECM) and making them resistant to apoptosis
[18]. Studies have also shown that COX-2 inhibitors are
anti-angiogenic [19,20].
Decorin (DCN) is small leucine-rich proteoglycan found
in many connective tissues. It converges with EGF func-
tionally to regulate the cell cycle through a pathway that
leads to growth suppression. Several studies have shown
that wild-type decorin has the ability to reduce VEGF lev-
els in tumors [21]. The authors of this study hypothesized
that if native decorin could be released and spread dif-
fusely through the stroma, it could stop growing tumor
cells by suppressing the production of a powerful ang-
iogenic stimulus. However, there is limited information
on decorin expression levels and molecular studies of
decorin in prostate cancer [22].
Versican (VCN) is a large chondroitin sulphate proteogly-
can secreted by fibroblasts and malignant epithelial cells
have the ability to regulate versican secretion. TGF-β1, a
known proangiogenic factor, enhances the level of versi-
can accumulation in prostate cancer [23]. It is believed
that it plays a role in tumor progression by destabilizing
cell adhesion, hence promoting cell proliferation and
motility especially of endothelial cells [24].
We hypothesize that tumor angiogenesis and subsequent
progression is modulated by complex interplay between
tumor cells and stromal components through expression
of various biological macromolecules. Therefore, analysis
of comprehensive expression status of these molecules
may help design better intervention strategies for anti-
angiogenic therapy in prostate cancer.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/34
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Results and Discussion
We have examined a total of 42 prostate archival tissue
specimens from Indian and American populations that
are geographically different with varying lifestyles. Ethnic-
ity, diet and treatment regimens have been reported to
cause variance in prostate cancer incidence and progres-
sion rates [25–28]. We specifically looked for differences
in angiogenic status and respective modulators between
PCa specimens from India and USA. The specimens were
classified accordingly into areas of BPH, atrophy, moder-
ately differentiated PCa, poorly differentiated PCa or
stroma. Though the classification was done as per the
major area represented in the specimens, individual
islands of BPH, high grade PIN, atrophy or PCa were
present within the same specimen, thereby providing us
an opportunity to observe differences in staining inten-
sity. As mentioned in the methods section, the Gleason
grades of PCa tissues ranged from 6–10, thus no well-dif-
ferentiated PCa (Gleason grade 2–4) were available for
our study. The representative progression stages for H & E
stained prostate tissue specimens of various stages are pre-
sented in Fig. 1A,1B,1C,1D. Figures for atrophy were not
included as it a common veritable feature in either BPH or
PCa in elderly men. The results of our comprehensive
immunohistochemical profiling studies and scoring data
of respective stage specific biomarkers are shown in Table
1. The significant correlation statistics had p ≤ 0.05.
CD34 is a myeloid progenitor cell antigen that is found in
endothelial cells. This biomarker can be found in all types
of endothelial cells and has been used previously to corre-
late angiogenesis in different stages of cancer [29]. We
have used this endothelial marker to correlate overall ang-
iogenesis status in prostate cancer samples used in our
studies (Fig. 1E,1F,1G,1H). Strong staining intensity for
CD34 was observed in endothelial cells associated with
high grade PIN (MVD~20.0), where as no CD34 staining
was seen in BPH. We observed intra- and inter-nodular
staining of microvessels and organizing endothelial cells
within the stromal compartment in MD PCa (MVD~9.0)
or PD PCa (MVD~36.0) specimens. As mentioned earlier,
the staining pattern of the endothelial cell specific marker
CD34 in these prostate tissues was carried out to correlate
the stage specific extent of angiogenesis as a combined
effect of all the markers studied. We found that areas
around PIN stain heavily for CD34. The interstitial tissues
of prostate carcinoma also stained positive implying that
angiogenesis is a universal phenomenon in prostate can-
cer progression from premalignancy to malignant stages
but the players regulating the process may be different and
sequential at each stage.
The immunostained sections of prostate archival speci-
mens showed that Anx-II expression was lost with malig-
nant transformation in prostate cancer (Fig.
2A,2B,2C,2D). None of the MDPCa or PD PCa specimens
(0%) from India expressed detectable Anx-II as compared
to BPH or atrophy where 75–100% stained positive. The
95 % confidence limit for loss of ANX-II had a correlation
coefficient of 0.015. Anx-II staining intensity was stronger
in areas of atrophy than in BPH samples. In BPH the stain-
ing was mainly on luminal edge of glandular epithelial
cells while in atrophy it was more cytoplasmic and mem-
brane bound. Because it is still expressed heterogeneously
in low grade PIN with diminishing intensity levels, but
not in high grade PIN or prostate adenocarcinoma, loss of
Anx-II may be a possible biomarker for impending malig-
nancy of PIN into advanced prostate cancer. The individ-
ual acini of PIN at the same time correlates with intense
staining for endothelial marker CD34 and therefore could
well be a stage specific to "angiogenic switch". A threshold
intensity level and extent of CD34 staining needs to be
defined further using quantitative criteria for pathological
implications of angiogenesis in PCa progression. Most of
the Anx-II was observed as membrane staining in the pros-
tate epithelial cells in contrast to cytoplasmic staining in
infiltrating immune cells (lymphocytes and mast cells).
The stromal fibroblasts expressed weaker intensity as
compared to any prostate epithelial cells. We also
observed membrane staining of nerves in few samples.
On examination of poorly-differentiated PCa (Gleason
grade greater than 8) from American specimens, we found
intense focal membrane staining in about 0–25 % cells
(Fig. 3), and this was not observed in corresponding
Indian specimens. These observations are surprising but
consistent with absence or greatly reduced expression of
Anx-II in androgen-responsive LNCaP-R and androgen-
unrepsonsive LNCaP-UR, MDA PCa 2A and 2B cell lines,
but expression of the protein in the metastatic androgen-
unresponsive PC-3 and DU-145 cell lines (Fig. 4).
Previous studies by Chetcuti et al., [30] showed that treat-
ment of LNCaP cells with the methylation inhibitor 5-aza-
2'-deoxycytidine (Aza-dC) resulted in reexpression of
annexin II, leading the authors to conclude that annexin
II is silenced in LNCaP cells by methylation. Treatment
with Aza-dC appears to reactivate many genes at the tran-
scriptional level, without a corresponding reactivation at
the protein level. We examined if annexin II protein
appears in Aza-dC treated LNCaP cells (Fig. 5). Robust
mRNA expression of annexin II is observed in LNCaP cells
after Aza-dC treatment (Fig. 5 panel A). However, when
protein levels are examined by immunoblot analysis, we
find that Aza-dC-treated LNCaP cells do not express
annexin II protein (Fig. 5 panel B). Our data lead us to
conclude that methylation status does not account solely
for silencing of annexin II in LNCaP cells.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/34
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The photomicrograph of representative prostate archival specimens stained with H&E. (A-D) shows areas of BPH, high grade  PIN, moderately-differentiated and poorly-differentiated prostate adenocarcinoma (PCa) and residual normal glands (indicated  as open arrows) Figure 1
The photomicrograph of representative prostate archival specimens stained with H&E. (A-D) shows areas of BPH, high grade 
PIN, moderately-differentiated and poorly-differentiated prostate adenocarcinoma (PCa) and residual normal glands (indicated 
as open arrows). Immunostaining for endothelial cell specific marker (anti-CD34, E-H) at magnification × 200 shows the extent 
of anti-CD34 stained organizing endothelial cell in areas of PIN as well as intraductal venule cross-sections in PCa (indicated as 
stealth arrows). No CD34 staining was seen in BPH area.
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Our results indicate that COX-2 is expressed at moderate
amounts in high grade PIN (50–75%) indicating ang-
iogenic switch in contrast to BPH and atrophy, and is a
causal event for prostate cancer progression through pro-
motion of angiogenesis. COX-2 expression was also
observed in 26–50 % of moderately-differentiated PCa
samples but weak focal expression (0–25 % cells) was
seen in poorly differentiated PCa (Fig. 2E,2F,2G,2H).
However, the smooth muscle cells of stroma and blood
vessels in the vicinity of high grade PCa of Gleason grade
of more than 7 were intensively stained for COX-2, indi-
cating possible contribution of extracellular matrix mod-
ulation in prostate cancer progression. The 95 %
confidence limit for COX-2 expression had correlation
coefficient of 0.019. Multiple activities of COX-2 have
been shown to regulate angiogenesis, increase cellular
adhesion to the extracellular matrix, and make cells resist-
ant to apoptosis. Therefore, biology of prostate cancer and
progression to metastasis needs to be looked at total
tumor environment milieu and not just at prostate epithe-
lial cell level. All of the BPH samples were weakly positive
for this biomarker. All other prostate specimens including
BPH exhibited weak to moderate staining of the stromal
fibroblast or smooth muscle cells depending on differen-
tiation stage of nearby prostate epithelial population. We
also observed staining of seminal vesicles cells adjacent to
the prostate tissue. We observed that COX-2 staining in
American population was generally more intense than
corresponding specimens from Indian population.
Two extracellular proteoglycans implicated in angiogen-
esis, invasion and metastasis viz. DCN and VCN were also
studied. We find that DCN expression is negative in pros-
tate epithelial cells from all lesions with exception of PIN
(Fig. 6A,6B,6C,6D). However, decorin was expressed in
only 26–50% of PIN samples and was heterogeneous in
distribution. Decorin is believed to have anti-angiogenic
and tumor suppressor activities [31]. Since carcinoma
cells do not express decorin, both of the properties men-
tioned previously are presumably lost. This biomarker
was strongly expressed in stromal cells in BPH with 100%
of specimens staining positive which diminishes in inten-
sity with sequential progressive stages. Stromal expression
of decorin is expected since it also functions in collagen
fibrillogenesis and extracellular matrix organization [32].
In contrast to the lack of DCN expression in tissue
specimens, we find that prostate cancer cell lines express
DCN (Figure 4). Highest DCN expression was observed in
the androgen-unresponsive PC-3 and DU-145 cell lines.
The androgen-sensitive LNCaP cells express DCN, while
the other androgen-sensitive MDA PCa 2A and 2B cell
lines appear to express a truncated form of DCN.
VCN was expressed in both moderately-differentiated
(50–75 %) and poorly-differentiated (1–25 %) PCa and
were mostly restricted to a focal group of cells (Fig.
6E,6F,6G,6H). VCN is known to promote cell prolifera-
tion and endothelial migration by destabilizing cell adhe-
sion and promoting invasion into vascular stroma. Again
our studies show that carcinoma cells strongly express this
biomarker, hence the spread of malignant cells is pro-
moted in conjunction with organizing endothelial cells.
Our study also shows that 26–50 % of the cells in PIN are
negative for VCN, but malignant cells over express, with
polarity of staining towards the migratory apex of invasive
epithelial cells. It needs to be mentioned here that in high-
grade cribiform invasive PCa specimens the intensity of
VCN staining was quite intense in almost all of epithelial
cells. Therefore proteoglycan expression switch (DCN to
VCN) occurs simultaneous to decorin loss and represents
sequential expression pattern that possibly controls over-
all angiogenesis in progression stages. However, VCN was
also expressed strongly in most of the BPH and atrophy
samples but its role in these pathological conditions
remains unclear, as we have not seen any correlating ang-
iogenesis. VCN is expressed weakly in the stromal com-
partment as well (100%).
Table 1: Angiogenesis modulating biomarker status in various prostate archival specimens. (n= 42)
Antigen BPH Atrophy PIN MD PCa PD PCa Stroma
Annexin II +(3) ++(4)* ++(2)* -(4) -(3) +(4)
Cyclooxygenase-2 +(4) +(4)+ + ( 3 ) * + ( 2 )+ ( 1 )+ + ( 2 ) *
Decorin -(4) -(4) ++(2)* -(4) -(4) +++(4)*
Versican ++(4) + (4) +(2) + (3) ++(1) +(3)
CD34 -(4) +(4) ++(3)* +(1) ++(3)* ND
$ Benign Prostatic Hyperplasia (BPH), high-grade Prostatic Intraepithelial Neoplasia (PIN), moderately-differentiated prostate adenocarcinoma (MD 
PCa), poorly-differentiated prostate adenocarcinoma (PD PCa), not determined (ND). Staining Intensity was scored as negative(-), weak (+), 
moderate (++) or strong (+++). Average percentage of cells were estimated and placed empirically into four categories 1–25%, 26–50%, 51–75%, 
or 75–100% and denoted in parenthesis as (1), (2), (3) or (4) respectively. The combination factor (product) of staining intensity and percentage of 
cells was used for statistical significance analysis of the data. Significant correlation is denoted as '*' for p ≤ 0.05. The 95 % confidence limits for 
correlation coefficient were negative for Anx-II (0.015) and positive for COX-2 (0.019) expression in PCa.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/34
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The photomicrograph of representative prostate archival specimens immunostained with anti-Anx-II (A-D) and anti-COX-2 (E- H) antibodies at magnification × 200 shows positively stained Anx-II regions of normal epithelia (open arrows) and BPH as  opposed to loss of Anx-II in PCa Figure 2
The photomicrograph of representative prostate archival specimens immunostained with anti-Anx-II (A-D) and anti-COX-2 (E-
H) antibodies at magnification × 200 shows positively stained Anx-II regions of normal epithelia (open arrows) and BPH as 
opposed to loss of Anx-II in PCa. High grade PIN is negative. The COX-2 immunostaining staining is present in high grade PIN 
but decreases in intensity from moderately-differentiated carcinoma to poorly-differentiated carcinoma. BPH and normal epi-
thelia are negative. The stromal cells in the areas of poorly differentiated PCa however stain strongly.
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Representative magnified images of high grade PCa specimens from American (panel A) and Indian (panel B) shows distinct pat- tern of Anx-II immunostaining Figure 3
Representative magnified images of high grade PCa specimens from American (panel A) and Indian (panel B) shows distinct pat-
tern of Anx-II immunostaining. Intense focal staining of cell membranes in American specimens contrasts to very weak staining 
in Indian specimens.
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Conclusions
It is believed that Anx-II plays a role in the pro- and anti-
angiogenic switch mechanism and that it may contribute
to invasive potential through extracellular matrix degrada-
tion through increased plasminolysis at the cell surface
[33]. Through plasmin reductase activity of its own or in
association of phosphoglycerate kinase (PGK) it may give
rise to an anti-angiogenic factor – angiostatin [34] as well
as affect DNA replication and cell proliferation [35]. The
mechanistic role of Anx-II in control of the "angiogenic
switch" remains an area of active investigation by our
group as well as others. Based on our results we suggest
that COX-2 probably cooperates in modulation of angio-
genesis and VCN modulates adhesion [36] of invasive
tumor cells to organizing endothelial cells while loss of
Anx-II and DCN is unable to restrict the cell proliferation
and angiogenesis respectively in prostate cancer. On the
other hand, intense membrane staining may aid in angio-
genesis and subsequent metastasis in high grades of pros-
tate cancer due to neovascular stroma generation. The
tissue remodeling events associated with dissemination of
tumor cells into other organs as well as failure of immu-
nosurveilance mechanisms with enhanced angiogenesis
may thus play together in tumor progression. Aptly, major
angiogenic factors such as VEGFs have also been shown to
down-regulate natural immune response as well [37]. Fur-
ther studies are necessary to understand the intricate
cooperative mechanisms of these biomarkers that affect
tumor progression through modulation of angiogenesis
and innate immunity.
Western Blot profile of Anx-II and DCN expressed in prostate cancer cell lines Figure 4
Western Blot profile of Anx-II and DCN expressed in prostate cancer cell lines. Each lane was loaded with 20 µg of total pro-
tein from lysates of indicated cell lines and detected with appropriate antibodies as mentioned in methods section. The samples 
are HPV-18C-1 (lane 1), LNCaP-R (lane 2), LNCaP-UR (lane 3), PC-3 (lane 4), DU-145 (lane 5), MDA PCa 2A (lane 6) and 
MDA PCa 2B (lane 7). PGK was included as internal control.
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Additionally, since Anx-II is expressed in BPH and atrophy
but not expressed in high-grade PIN or malignant cells, it
could be a specific marker for progression of prostate
cancer. Nuclear accumulation of Anx-II is a negative regu-
lator of prostate cell proliferation [38]. However, the
mechanisms of cellular proliferation control may be dif-
ferent due to localization of Anx-II, and has been demon-
strated in breast, colorectal, hepatic or hematological
malignancies [15,39–41]. The focal membrane staining of
Anx-II in high grade PD PCa in American specimens cor-
relates with Anx-II expression in the metastatic prostate
carcinoma cell lines PC-3 and DU-145. The loss of Anx-II
in PCa appears to involve multiple mechanisms, and
DNA methylation does not appear to be the sole process.
The mechanisms leading to reappearance of Anx-II in high
grade PCa and in metastatic cell lines are yet unknown
and need further investigation.
The up-regulated COX-2 and VCN expression in prostate
adenocarcinoma stages support the notion that different
biomolecules could be factor for tumor angiogenesis,
invasion, dissemination to organs contributing individu-
ally in each stage of progression and metastasis. COX-2 is
known modulator of apoptosis and angiogenesis as dis-
cussed in the introduction while VCN is an anti-adhesive
molecule which helps in dissemination of prostate cells.
Anx-II mRNA expression, but not protein, is induced by 5-aza-2'-deoxycytidine, A: LNCaP and DU-145 cells were treated with  or without 3 µM 5-aza-2'-deoxycytidine for 48 hours, and the annexin II expression was measured by RT-PCR Figure 5
Anx-II mRNA expression, but not protein, is induced by 5-aza-2'-deoxycytidine, A: LNCaP and DU-145 cells were treated with 
or without 3 µM 5-aza-2'-deoxycytidine for 48 hours, and the annexin II expression was measured by RT-PCR. M: marker; lane 
1: untreated LNCaP; lane 2: Aza-dC treated LNCaP; lane 3 untreated DU-145; lane 4 Aza-dC treated DU-145. B: LNCaP cells 
were treated with or without 3 µM 5-aza-2'-deoxycytidine for 48 hours. 10 µg of total protein was subjected to Western blot 
as described in Materials and Methods. 10 µg of whole cell extract of K562 cells was used as a positive control. Lane 1: treated 
LNCaP; Lane 2: untreated LNCaP; Lane 3: mock-treated LNCaP (with Lipofectamine); Lane 4: K562 cell extract. The bottom 
panel shows expression of an internal control in the same samples. PGK was used as an internal control.
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The photomicrograph of representative prostate archival specimens stained with anti-DCN (A-D) and anti-VCN (E-H) at mag- nification × 200 shows only PIN regions as DCN positive while BPH, moderately-differentiated and poorly-differentiated carci- nomas are negative Figure 6
The photomicrograph of representative prostate archival specimens stained with anti-DCN (A-D) and anti-VCN (E-H) at mag-
nification × 200 shows only PIN regions as DCN positive while BPH, moderately-differentiated and poorly-differentiated carci-
nomas are negative. VCN staining is strongly positive in BPH and moderately-differentiated carcinoma while poorly-
differentiated carcinoma shows moderate staining. PIN is negative for VCN expression.
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The negative modulator in such processes such as decorin
is lost upon malignant transformation and unable to
check TGF-β mediated constitutive signaling. This also
supports our hypothesis that tumor progression is modu-
lated by interactions between tumor cells and stromal
components and anti-angiogenic strategies can be based
on combinatorial approach targeting various modulators
simultaneously. Since existing literature supports the view
that all of the angiogenesis modulators studied by us are
regulated in the TGF-β pathway dependent manner, it
remains to be investigated whether TGF-β signaling
antagonists will show therapeutic efficacy in preventing
prostate cancer angiogenesis and progression in future.
Methods
Tissue specimens and Cell lines
The prostate tissue archival specimens were core needle
biopsies, transurethral resection specimens (TURPs) or
radical prostatectomy from patients with prostate adeno-
carcinoma and were obtained from the All India Institute
of Medical Sciences (AIIMS) in New Delhi, India and Uni-
versity of Nebraska Medical Center (UNMC), Omaha,
USA. These specimens were used according to
institutional guidelines and approved protocols from
UNMC Institutional Review Board. In total, 17 core nee-
dle biopsies from India and 25 US specimens comprising
of radical prostatectomy (23) and TURPs (2) were exam-
ined by immunohistochemistry for profiling the
angiogenesis modulator biomarkers. Two anatomic
pathologists independently graded the H&E stained paraf-
fin sections from the same block to determine the Gleason
scores. The Gleason grades for these cancers varied
between 6 and 10. The presence of BPH, high grade PIN
and atrophy was recorded. The archival tissues samples
examined were heterogeneous in distribution of different
type of progression stages and consisted of distinct regions
of BPH, atrophy, PIN, MD PCa or PD PCa in combination
within same specimen.
HPV-18 C-1 cells were grown in Keratinocyte-SFM supple-
mented with bovine pituitary extract (25 µg/ml) and
recombinant epidermal growth factor (0.15 ng/ml).
LNCaP-R and LNCaP-UR cells [42] were maintained in
RPMI 1640 supplemented with 7% FBS and 1% PS. DU-
145 and PC-3 were maintained in DMEM supplemented
with 5% FBS and 1% PS. MDAPCa 2A and 2B cells were
maintained in BRFF media (Biological Research Faculty
and Facility, Inc, Ijamsville, MD, USA) supplemented
with 20% FBS and 1% PS. Cells were routinely fed with
fresh media and incubated in a 37°C incubator at 5%
CO2.
Immunohistochemistry
Neutral buffered formalin fixed and paraffin embedded
tissue sections (5 µm) were treated with EZ-DeWax™ solu-
tion (Biogenex Inc., San Ramon, CA) for 10 minutes fol-
lowed by a rinse with deionized water for 2 minutes.
Tissue sections were rehydrated with phosphate buffered
saline (PBS) and treated subsequently with 0.3% H2O2 in
absolute methanol for 30 minutes to block endogenous
peroxidase activity. The slides were washed three times
with PBS and immersed in 2.5% normal horse serum
(Vector Laboratories, Burlingame, CA) for 30 minutes to
inhibit nonspecific binding. To reduce the amount of free
avidin and biotin in the tissue, the slides were incubated
in avidin and biotin blocking solutions (Vector Laborato-
ries, Burlingame, CA) for 15 minutes each. The tissue sec-
tions were then incubated in primary antibody overnight
at 4°C. Primary antibodies used are as follows: polyclonal
goat anti-human COX-2 (cat # sc1745; SantaCruz Bio-
technology Inc, Santa Cruz, CA, 1:250 dilution), Anx-II
(α-774, 1:1000 dilution [43]), VCN (LF-99; 1:1000 dilu-
tion [44]), DCN (cat # AF-143; R & D Systems, MN, 1:100
dilution), and antibody against CD34 (gift from Dr.
Rakesh Singh, University of Nebraska Medical Center, NE,
1:75 dilution). Slides were washed with PBS and incu-
bated for 30 minutes with biotinylated anti-mouse/rab-
bit/goat antibody (H+L) made in horse (Vector
Laboratories, Burlingame, CA). After washing in PBS, the
sections were treated with Streptavidin / Peroxidase com-
plex solution (Vector Laboratories, Burlingame, CA) for
45 minutes. Visualization of signal was achieved with
incubation in a substrate solution composed of 250 µL
Tris pH 7.5, 2.5 mg diaminobenzidine tetrachloride
(DAB) and 1.7 µL 0.3% H2O2 in 5 mL of ddH2O for up to
two minutes. Sections were counterstained with hematox-
ylin and mounted using Vectamount medium (Vector
Laboratories, Burlingame, CA). All procedures were car-
ried out at room temperature unless otherwise specified.
Slides were examined in blinded manner by a pathologist
and scored for staining intensity & percentage of stained
cells. The combined score of staining intensity and per-
centage of stained cells (greater than 5 %) was considered
positive staining for each type of samples. Statistical sig-
nificance analysis was performed using correlation coeffi-
cient test as described earlier [45]. Average microvessel
density (MVD) was enumerated by counting CD 34 posi-
tive sprouting tubular structures at 400× magnification of
stained slides in different stages of PCa.
RT-PCR
Total RNA was extracted from LNCaP and DU-145 cell
lines using RNeasy Kit (Qiagen, CA). First Strand cDNA
was synthesized from 1 µg RNA with Oligo dT as primer
using SuperScript RTs (Invitrogen). One quarter of each
RT product was added to PCR mixtures (50 µl), which
contained 2.5 U Taq DNA polymerase and buffer
(Promega), 200 µM dNTPs and 0.5 µM of annexin II-spe-
cific primers ANX-II-F (5'-AACACATTGGCCTCAGGAAG-
3') and ANX-II-R (5'-CAGGAATGCTTAGGCAACT-3').Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/34
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These primers span part of the 3'and 5'-untranslated
region. The PCR temperature program was 94°C for 30
seconds, 60°C for 1 minute, and 72°C for 1 minute for 30
cycles with a final 10 minutes extension at 72°C. 15 µl of
each PCR product was taken for electrophoresis in 0.8%
agarose gel and the gel was stained with ethidium bro-
mide. The gel was visualized with UV light and
photographed.
Western Blot analysis
Protein extracts were prepared from prostate cancer cell
lines using a protein lysis buffer containing 50 mM Tris-
HCl, pH 7.5, 2.0 mM phenylmethylsulfonyl fluoride
(PMSF), 5.0 mM iodoacetamide, 5.0 mM ethylene
diamine tetraacetic acid (EDTA), 150 mM NaCl, 0.5%
nonylphenoxy polyethoxy ethanol (NP-40), and 0.5%
nonanoyl-N-methylglucamide (Mega-9). Protease inhibi-
tors leupeptin (2 µg/ml) and pepstatin (1 µg/ml) (Roche,
Mannheim, Germany) were added just prior to the addi-
tion of lysis buffer to the cells. Protein concentrations in
the extracts were quantitated using bicinchoninic acid
(BCA) protein assay (Pierce, Rockford, IL). From each
extract, 20 µg of total protein were separated on a 12%
SDS-PAGE with a 5% stacking gel. After electrophoresis,
proteins were transferred to 0.2 µm PVDF membranes
(Millipore, Bedford, MA) using transfer buffer that con-
tained 25 mM Tris-HCl and 700 mM glycine. Membranes
were blocked in 7% powdered milk dissolved in 1X TTBS
buffer (14 mM Tris, 154 mM NaCl, and 0.5 % Tween-20,
pH adjusted to 7.5 with HCl) overnight at 4°C. Primary
antibodies were incubated for 2 hours at room tempera-
ture in 5% powdered milk dissolved in 1X TTBS. Primary
antibodies used were monoclonal mouse anti-human
Annexin II (BD Biosciences) at 1:5000 dilution and poly-
clonal rabbit antiserum against human Decorin (LF136,
obtained from Dr. Larry Fisher, NIH) at 1:4000 dilution.
The membranes were washed in 1X TTBS for three times,
15 minutes each at room temperature (RT). Appropriate
secondary antibodies conjugated to horseradish peroxi-
dase (Promega, Madison, WI) were incubated with respec-
tive membranes for 1 hour at RT. Follwing Five
intermittent washes with 1X TTBS membranes were devel-
oped using ECL+ (Amersham Pharmacia Biotech, Arling-
ton Heights, IL) and films exposed for appropriate times
to detect signal. Immunoblot for 3-phosphoglycerate
kinase (PGK) was used as an internal control for gel
loading.
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